CCCC vs KYMR

For growth investors, C4 Therapeutics, Inc.

(CCCC) is the stronger pick with 1. 0% revenue growth year-over-year, versus -16. 7% for Kymera Therapeutics, Inc. (KYMR). Analysts rate C4 Therapeutics, Inc. (CCCC) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Kymera Therapeutics, Inc.

(KYMR) delivered a total return of +110. 5%, compared to -91. 2% for C4 Therapeutics, Inc. (CCCC). Over 10 years, the gap is even starker: KYMR returned +159. 4% versus CCCC's -88. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Kymera Therapeutics, Inc.

(KYMR) is the lower-risk stock at 1. 15β versus C4 Therapeutics, Inc. 's 2. 35β — meaning CCCC is approximately 105% more volatile than KYMR relative to the S&P 500. On balance sheet safety, Kymera Therapeutics, Inc. (KYMR) carries a lower debt/equity ratio of 5% versus 23% for C4 Therapeutics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), C4 Therapeutics, Inc.

(CCCC) is pulling ahead at 1. 0% versus -16. 7% for Kymera Therapeutics, Inc. (KYMR). On earnings-per-share growth, the picture is similar: C4 Therapeutics, Inc. grew EPS 16. 4% year-over-year, compared to -23. 8% for Kymera Therapeutics, Inc.. Over a 3-year CAGR, CCCC leads at 5. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

C4 Therapeutics, Inc.

(CCCC) is the more profitable company, earning -292. 1% net margin versus -794. 4% for Kymera Therapeutics, Inc. — meaning it keeps -292. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CCCC leads at -290. 7% versus -891. 3% for KYMR. At the gross margin level — before operating expenses — KYMR leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Kymera Therapeutics, Inc.

(KYMR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 15), +159. 4% 10Y return). C4 Therapeutics, Inc. (CCCC) carries a higher beta of 2. 35 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (KYMR: +159. 4%, CCCC: -88. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.